<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073148</url>
  </required_header>
  <id_info>
    <org_study_id>113133</org_study_id>
    <nct_id>NCT03073148</nct_id>
  </id_info>
  <brief_title>Evaluation of Tangible Boost Replenishing System</brief_title>
  <official_title>Evaluation of Tangible Boost Replenishing System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tangible Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tangible Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate Tangible Boost, a new contact lens care product which is designed to&#xD;
      replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG&#xD;
      coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens&#xD;
      surface. This coating improves lens wettability, a common cause of patient discomfort.&#xD;
      Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the&#xD;
      lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each&#xD;
      month at home.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2/3 of patients will be assigned to the Tangible Boost treatment arm of the study, and 1/3 of patients will be assigned to the placebo control arm.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Event Reports or Discontinuations</measure>
    <time_frame>Duration of study, 90 +/- 7 days after lens dispense visit.</time_frame>
    <description>A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
    <description>Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
    <description>Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-invasive Tear Film Break-up Time</measure>
    <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
    <description>Tear break-up time was measured with the OCULUS Keratograph.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acceptable Lens Fit</measure>
    <time_frame>final assessment (day 90)</time_frame>
    <description>Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CLDEQ Score</measure>
    <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
    <description>The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
    <description>The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Contact Lens Solution</condition>
  <arm_group>
    <arm_group_label>Tangible Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tangible Boost</intervention_name>
    <description>Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
    <arm_group_label>Tangible Boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo saline</intervention_name>
    <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Habitual contact lens wear with a group 3 FDA approved rigid lens material, with&#xD;
             20-50% of subjects wearing corneal lenses&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eye injury or surgery within the 3 months immediately prior to enrollment for this&#xD;
             trial&#xD;
&#xD;
          -  Pre-existing ocular irritation that would preclude contact lens fitting&#xD;
&#xD;
          -  Current enrollment in an ophthalmic clinical trial&#xD;
&#xD;
          -  Evidence of systemic or ocular abnormality, infection, or disease which is likely to&#xD;
             affect successful wear of contact lenses or use of the accessory solutions, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Any use of medications for which contact lens wear could be contraindicated, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  Visual acuity less than 20/20 when best corrected with contact lenses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria K Walker, OD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tangiblescience.com</url>
    <description>Tangible Science website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <results_first_submitted>September 29, 2020</results_first_submitted>
  <results_first_submitted_qc>October 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2020</results_first_posted>
  <disposition_first_submitted>January 31, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 23, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 17, 2020</disposition_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact Lens Care Accessory</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03073148/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Upon enrollment in the study, patients received Hydra-PEG coated fluorosilicone acrylate RGP contact lenses. Assignment to the Tangible Boost or Control group occurred after 1 month of contact lens wear, on day 30. 4 participants that did not report back for visit 3 on day 30 were excluded from the study prior to assignment to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tangible Boost</title>
          <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
        </group>
        <group group_id="P3">
          <title>Unassigned</title>
          <description>Subjects that did not report back for visit 3 and were therefore not assigned to a treatment group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline measures are provided for all participants who were assigned to a study arm. Participants who dropped out of the study prior to assignment are not included.</population>
      <group_list>
        <group group_id="B1">
          <title>Tangible Boost</title>
          <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="16"/>
                    <measurement group_id="B2" value="46" spread="16"/>
                    <measurement group_id="B3" value="47" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corneal Staining</title>
          <description>Corneal staining with lissamine green was used to identify damage to the corneal cells, which could have been caused by the contact lenses or treatments in the study. 5 regions in each eye were score on a scale of 0-4, resulting in a total possible range of 0-20. A higher score indicates more corneal damage. Left and right eye scores were averaged for each subject. Baseline data was collected after 1 month of lens wear in the study just prior to initial lens treatment with Tangible Boost or placebo control.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="0.25" upper_limit="3.75"/>
                    <measurement group_id="B2" value="2.0" lower_limit="0" upper_limit="5.63"/>
                    <measurement group_id="B3" value="2.0" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity (logMAR)</title>
          <description>Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. Baseline measurements were collected after 1 month of lens wear, prior to treatment with Tangible Boost or the placebo solution. A score of &quot;0&quot; indicates no vision loss, with higher scores indicating poorer vision.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.11" lower_limit="0.01" upper_limit="0.20"/>
                    <measurement group_id="B2" value="0.11" lower_limit="-0.02" upper_limit="0.23"/>
                    <measurement group_id="B3" value="0.11" lower_limit="0" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-invasive tear film break-up time</title>
          <description>Tear break-up time was measured with the OCULUS Keratograph prior to lens treatment with Tangible Boost or the placebo, after 1 month of lens wear in the study.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.40" spread="4.81"/>
                    <measurement group_id="B2" value="14.91" spread="6.48"/>
                    <measurement group_id="B3" value="16.59" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens Fit</title>
          <description>Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CLDEQ Score</title>
          <description>The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort. Baseline measurements were collected prior to lens treatment after 1 month of lens wear.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="7"/>
                    <measurement group_id="B2" value="10" spread="8"/>
                    <measurement group_id="B3" value="14" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>The subjective comfort of lenses was evaluated on a scale of 1-100, with higher scores indicating better comfort.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="28"/>
                    <measurement group_id="B2" value="84" spread="22"/>
                    <measurement group_id="B3" value="73" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Event Reports or Discontinuations</title>
        <description>A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.</description>
        <time_frame>Duration of study, 90 +/- 7 days after lens dispense visit.</time_frame>
        <population>All subjects enrolled in the study were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
          <group group_id="O3">
            <title>Unassigned</title>
            <description>Dropped out of study prior to assignment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Event Reports or Discontinuations</title>
          <description>A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.</description>
          <population>All subjects enrolled in the study were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining</title>
        <description>Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.</description>
        <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
        <population>All participants that were assigned to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining</title>
          <description>Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.</description>
          <population>All participants that were assigned to a study arm.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit=".5" upper_limit="5.125"/>
                    <measurement group_id="O2" value="2.00" lower_limit=".75" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O2" value="1.75" lower_limit="0.75" upper_limit="4.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.3577</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.9917</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.</description>
        <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
        <population>All participants assigned to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.</description>
          <population>All participants assigned to a study arm.</population>
          <units>logMAR visual acuity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="-.025" upper_limit="0.165"/>
                    <measurement group_id="O2" value="0.095" lower_limit="-0.07" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>final assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" lower_limit="0.020" upper_limit="0.225"/>
                    <measurement group_id="O2" value="0.060" lower_limit="-0.0225" upper_limit="0.2725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.3239</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.8343</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-invasive Tear Film Break-up Time</title>
        <description>Tear break-up time was measured with the OCULUS Keratograph.</description>
        <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
        <population>All participants that were assigned to a study arm. 1 participant was excluded due to malfunction of the keratograph during their visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-invasive Tear Film Break-up Time</title>
          <description>Tear break-up time was measured with the OCULUS Keratograph.</description>
          <population>All participants that were assigned to a study arm. 1 participant was excluded due to malfunction of the keratograph during their visit.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.27" spread="4.32"/>
                    <measurement group_id="O2" value="19.84" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>final assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.84" spread="4.64"/>
                    <measurement group_id="O2" value="18.30" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.4134</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.1192</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acceptable Lens Fit</title>
        <description>Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).</description>
        <time_frame>final assessment (day 90)</time_frame>
        <population>All participants that were assigned to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acceptable Lens Fit</title>
          <description>Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).</description>
          <population>All participants that were assigned to a study arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLDEQ Score</title>
        <description>The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.</description>
        <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
        <population>All participants that were assigned to a study group.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>CLDEQ Score</title>
          <description>The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.</description>
          <population>All participants that were assigned to a study group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="8.9"/>
                    <measurement group_id="O2" value="7.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>final assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="8.0"/>
                    <measurement group_id="O2" value="11.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.1753</p_value>
            <p_value_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.1843</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS)</title>
        <description>The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.</description>
        <time_frame>1 day after treatment (day 31), final assessment (day 90)</time_frame>
        <population>All participants that were assigned to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Tangible Boost</title>
            <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.</description>
          <population>All participants that were assigned to a study arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="23"/>
                    <measurement group_id="O2" value="93" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>final assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="22"/>
                    <measurement group_id="O2" value="84" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.0765</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.1520</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tangible Boost</title>
          <description>Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.&#xD;
Tangible Boost: Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit containing saline after 30 days and again after 60 days.&#xD;
Placebo saline: Participants will treat their lenses with a placebo &quot;Tangible Boost&quot; kit, which contains saline in place of the Tangible Boost solution.</description>
        </group>
        <group group_id="E3">
          <title>Unassigned</title>
          <description>Dropped out of study prior to assignment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Hydrops</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asymptomatic keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mild, allergic-type reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acute inflammatory conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mild conjunctival inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Preservative toxicity-type corneal sensitivity</sub_title>
                <description>Occurs in scleral lens wearers when preservatives remain in the lens bowl.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Contact lens associated red eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Decline in performance of the Hydra-PEG lenses was not observed in the control group; therefore, there was little opportunity to see improvements in outcome measures in the treatment group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Research and Development</name_or_title>
      <organization>Tangible Science</organization>
      <phone>650-241-1045 ext 108</phone>
      <email>kelly@tangiblescience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

